ORFADIN Drug Patent Profile

Which patents cover Orfadin, and what generic alternatives are available?

Orfadin is a drug marketed by Swedish Orphan and is included in two NDAs. There is one patent protecting this drug.

The generic ingredient in ORFADIN is nitisinone. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the nitisinone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Orfadin

A generic version of ORFADIN was approved as nitisinone by NOVITIUM PHARMA on August 26^th, 2019.

Summary for ORFADIN

US Patents:	1
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	95
Clinical Trials:	12
Patent Applications:	711
Drug Prices:	Drug price information for ORFADIN
What excipients (inactive ingredients) are in ORFADIN?	ORFADIN excipients list
DailyMed Link:	ORFADIN at DailyMed

See drug prices for ORFADIN

Recent Clinical Trials for ORFADIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sutphin Drugs	N/A
Cycle Pharmaceuticals Ltd.	Phase 1
Parexel	Phase 1

See all ORFADIN clinical trials

Pharmacology for ORFADIN

Drug Class	4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor
Mechanism of Action	Cytochrome P450 2C9 Inhibitors Cytochrome P450 2E1 Inducers Hydroxyphenylpyruvate Dioxygenase Inhibitors Organic Anion Transporter 1 Inhibitors Organic Anion Transporter 3 Inhibitors

US Patents and Regulatory Information for ORFADIN

ORFADIN is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Swedish Orphan	ORFADIN	nitisinone	CAPSULE;ORAL	021232-001	Jan 18, 2002	AB	RX	Yes	No
Swedish Orphan	ORFADIN	nitisinone	CAPSULE;ORAL	021232-004	Jun 13, 2016	AB	RX	Yes	Yes
Swedish Orphan	ORFADIN	nitisinone	CAPSULE;ORAL	021232-002	Jan 18, 2002	AB	RX	Yes	No
Swedish Orphan	ORFADIN	nitisinone	CAPSULE;ORAL	021232-003	Jan 18, 2002	AB	RX	Yes	No
Swedish Orphan	ORFADIN	nitisinone	SUSPENSION;ORAL	206356-001	Apr 22, 2016		RX	Yes	Yes	9,301,932		Y

Expired US Patents for ORFADIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Swedish Orphan	ORFADIN	nitisinone	CAPSULE;ORAL	021232-001	Jan 18, 2002	5,006,158
Swedish Orphan	ORFADIN	nitisinone	CAPSULE;ORAL	021232-002	Jan 18, 2002	5,550,165
Swedish Orphan	ORFADIN	nitisinone	CAPSULE;ORAL	021232-002	Jan 18, 2002	5,006,158
Swedish Orphan	ORFADIN	nitisinone	CAPSULE;ORAL	021232-003	Jan 18, 2002	5,006,158
Swedish Orphan	ORFADIN	nitisinone	CAPSULE;ORAL	021232-001	Jan 18, 2002	5,550,165

EU/EMA Drug Approvals for ORFADIN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
MendeliKABS Europe Ltd	Nitisinone MDK (previously Nitisinone MendeliKABS)	nitisinone	EMEA/H/C/004281Treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT 1) in combination with dietary restriction of tyrosine and phenylalanine.	Withdrawn	yes	no	no	2017-08-24
Cycle Pharmaceuticals (Europe) Ltd	Nityr	nitisinone	EMEA/H/C/004582Treatment of adult and paediatric patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.	Authorised	yes	no	no	2018-07-26
Swedish Orphan Biovitrum International AB	Orfadin	nitisinone	EMEA/H/C/000555Hereditary tyrosinemia type 1 (HT 1)Orfadin is indicated for the treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT 1) in combination with dietary restriction of tyrosine and phenylalanine.Alkaptonuria (AKU)Orfadin is indicated for the treatment of adult patients with alkaptonuria (AKU).	Authorised	no	no	no	2005-02-21

International Patents for ORFADIN

When does loss-of-exclusivity occur for ORFADIN?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Croatia

Cyprus

Denmark

European Patent Office

Hungary

Israel

Japan

Mexico

New Zealand

Poland

Russian Federation

San Marino

Serbia

Slovenia

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ORFADIN around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	240669	NUEVOS COMPUESTOS DE 2-(2-BENZOILO SUSTITUIDO)CICLOHEXANO-1,3-DIONA (NEW 2-(2-SUBSTITUTED BENZOYL)-1,3-CYCLOHEXANEDIONES)
Argentina	240792	COMPUESTO DERIVADOS DE 2-(BENZOILO SUBSTITUIDO) -1,3 -CICLOHEXANODIONA Y COMPOSICION HERBICIDA QUE LOS COMPRENDE. (CERTAIN 2-(2-SUBSTITUTED BENZOYL)-1,3-CYCLOHEXANEDIONES)
Argentina	240794	DERIVADOS DE 2-(2'-NITROBENZOIL)-1,3-CICLOHEXANODIONA COMPOSICION HERBICIDA QUE LOS COMPRENDE Y PROCEDIMIENTO PARA PREPARARLOS.
Argentina	240909	DERIVADOS DE 2-(2'-ALQUILBENZOIL) -1,3-CICLOHEXANODIONA, COMPOSICION QUE LOS COMPRENDE Y PROCEDIMIENTO PARA PREPARARLO"
Austria	37531

Supplementary Protection Certificates for ORFADIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0591275	CA 2005 00029	Denmark
0591275	91180	Luxembourg		91180, EXPIRES: 20170618
0591275	SPC/GB05/030	United Kingdom		PRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221
0591275	05C0024	France		PRODUCT NAME: NITISINONE; REGISTRATION NO/DATE: EU/1/04/303/001 20050221
0591275	C300198	Netherlands		PRODUCT NAME: NITISINONE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT; REGISTRATION NO/DATE: EU/1/04/303/001-003 20050201

Orfadin Market Dynamics, Patent Position, Competition, and Financial Trajectory

Last updated: August 9, 2026

Orfadin is Sobi’s branded nitisinone product for hereditary tyrosinemia type 1, a rare, life-threatening metabolic disorder. Its commercial position rests on chronic treatment, high diagnosis sensitivity, limited patient numbers, and specialist distribution rather than broad prescription volume. The core molecule is mature, but Orfadin retains commercial value through established clinical use, global regulatory approvals, patient-support infrastructure, and differentiated dosage forms.

Sobi does not report a complete standalone Orfadin revenue series in its current headline financial disclosures. That limits precise product-level CAGR analysis. The available evidence supports a mature, defensible rare-disease franchise with exposure to branded competition, generic nitisinone entry, pricing pressure, and a gradual shift from capsule-led sales toward pediatric-friendly oral suspension.

What is Orfadin and which patients does it treat?

Orfadin contains nitisinone, a tyrosine metabolism inhibitor. It blocks 4-hydroxyphenylpyruvate dioxygenase, reducing the production of toxic metabolites that accumulate in hereditary tyrosinemia type 1, or HT-1.

HT-1 is caused by fumarylacetoacetate hydrolase deficiency. Untreated patients can develop severe liver disease, renal tubular dysfunction, neurologic crises, and hepatocellular carcinoma. Nitisinone is administered with dietary restriction of tyrosine and phenylalanine.

Attribute	Orfadin position
Active ingredient	Nitisinone
Primary indication	Hereditary tyrosinemia type 1
U.S. approval	FDA approval in 2002
European indication	HT-1; alkaptonuria authorization varies by product and jurisdiction
Main dosage forms	Capsules and oral suspension
Treatment duration	Generally chronic or lifelong
Prescribing channel	Metabolic disease specialists and hospital-linked centers
Commercial category	Orphan, ultra-rare metabolic disease
Main competitors	Nityr and other nitisinone products
Key commercial constraint	Small addressable population and specialist diagnosis

The FDA label specifies that Orfadin must be used with dietary restriction. The suspension is particularly relevant for infants and young children who cannot reliably swallow capsules. [1]

How large is the Orfadin market?

The addressable market is small by patient count but economically attractive because treatment is chronic and medically necessary.

Published epidemiology estimates for HT-1 vary by geography. Incidence is higher in certain regions, including parts of Scandinavia, the Middle East, and Quebec, because of founder effects, consanguinity, and population-specific genetic factors. Broader newborn screening has increased diagnosis and treatment before severe clinical deterioration.

The market has four structural characteristics:

1. Low patient volume: HT-1 is an ultra-rare disorder.
2. High treatment continuity: Patients who respond to nitisinone generally remain on therapy.
3. Limited substitution: Treatment changes require specialist oversight, particularly in children.
4. Global fragmentation: Reimbursement, newborn screening, and access differ materially by country.

The commercial opportunity extends beyond newly diagnosed patients. Existing patients require continued supply, dose adjustments as body weight changes, and formulations suitable for different ages. That creates recurring demand even when incidence is stable.

How newborn screening affects Orfadin demand

Newborn screening expands the treated population by identifying patients before liver failure or neurologic complications appear. Early diagnosis can increase the number of patients receiving long-term nitisinone while reducing the number progressing to transplantation.

Screening adoption is therefore a positive volume driver. The effect is gradual because it depends on national screening policy, laboratory infrastructure, confirmatory testing, and reimbursement.

What is Orfadin’s financial trajectory?

Sobi does not consistently disclose Orfadin revenue as a separate line item in its consolidated financial releases. The company reports results across broader product and business categories, which prevents a fully verified standalone revenue trend from public statutory disclosures.

The financial trajectory is best characterized as mature and recurring rather than high-growth.

Financial driver	Expected effect on Orfadin
Chronic lifelong therapy	Supports recurring revenue
Ultra-rare prevalence	Limits absolute revenue scale
Newborn screening	Provides gradual volume growth
Pediatric oral suspension	Protects access in younger patients
Nityr competition	Limits pricing and market-share expansion
Generic nitisinone	Creates longer-term price erosion risk
Global reimbursement	Produces regional price variation
Mature molecule	Reduces patent-driven pricing power
Sobi portfolio strategy	May reduce management focus relative to newer assets

Orfadin is strategically useful because it generates specialty revenue without the clinical-development risk associated with an early-stage asset. Its likely margin profile benefits from chronic use and limited manufacturing complexity, although patient-support, regulatory, distribution, and market-access costs reduce the contribution margin relative to a conventional high-volume tablet.

Sobi’s broader portfolio has increasingly emphasized hematology, immunology, and rare disease products with larger growth profiles. That makes Orfadin more likely to function as a stable cash-generating product than as a primary growth engine.

What patents protect Orfadin and nitisinone?

The core nitisinone molecule is old, and composition-of-matter protection is no longer the principal barrier to competition. The commercial protection surrounding Orfadin is more likely to involve product-specific formulation, dosage-form, manufacturing, and method-of-use rights.

Core molecule and formulation protection

The principal IP layers are:

• nitisinone composition-of-matter patents, which are generally expired or no longer commercially decisive;
• capsule formulation rights;
• liquid oral suspension formulations;
• dosing and administration methods;
• pharmaceutical composition and stability claims;
• manufacturing and quality-control processes;
• regulatory exclusivity and orphan-drug protections.

Formulation patents can be more important than molecule patents for pediatric products. A suspension that provides reliable concentration, stability, dosing accuracy, and storage performance may be difficult for a competitor to replicate without conducting formulation development and regulatory work.

The existence of a formulation patent does not necessarily prevent a competitor from launching a capsule or tablet. Patent scope depends on the asserted claims, expiration date, jurisdiction, and whether the competing product practices those claims.

Patent expiration and exclusivity

Protection type	Orfadin assessment
Core nitisinone patent	Mature and generally not the principal barrier
U.S. orphan exclusivity	Seven-year period associated with the original orphan approval; expired
Pediatric exclusivity	Any historical extension is no longer commercially active
Formulation protection	Potentially relevant, especially for oral suspension
Method-of-use protection	May cover selected dosing or disease-management uses
Regulatory exclusivity today	Primarily dependent on product-specific approvals and labeling
Trade-secret protection	Potentially relevant for manufacturing and quality processes

The original U.S. Orfadin approval occurred in 2002. The seven-year U.S. orphan-drug exclusivity period would have ended in 2009, subject to the precise approval and designation record. Orphan exclusivity is distinct from patent protection and does not prevent all products containing the same active ingredient from entering the market.

What is the FDA regulatory and Orange Book status of Orfadin?

Orfadin was approved by the FDA under NDA 021196 for HT-1. The approved products include capsule strengths and an oral suspension presentation. The FDA label requires concurrent dietary management and monitoring of plasma tyrosine levels. [1]

The FDA Orange Book remains the key source for determining listed patents and approved product status. Orange Book listings can change as patents expire, are delisted, or are superseded by updated product records. [2]

The relevant regulatory distinction is between:

• an ANDA generic product, which typically relies on bioequivalence and may submit Paragraph IV certifications against listed patents;
• a 505(b)(2) product, which may rely partly on existing safety and efficacy information but can have a distinct formulation or dosage form;
• a separate branded nitisinone product, such as Nityr, which can compete without being an Orfadin generic.

Does Orfadin face Paragraph IV challenges?

Paragraph IV risk is principally relevant to any unexpired Orange Book-listed patents. Because the active ingredient is mature and original orphan exclusivity has expired, the main potential targets would be formulation, dosage-form, or use patents.

Public FDA approval records identify competing nitisinone products, but the presence of a competitor does not by itself establish a successful Paragraph IV challenge. A generic applicant may certify that listed patents are expired, not infringed, or invalid, or may wait for patent expiry.

No major publicly established, industry-defining Paragraph IV litigation campaign against Orfadin is necessary to explain current competitive risk. The more important risk is ordinary market entry by approved nitisinone products and gradual payer substitution.

Which companies compete with Orfadin?

The leading direct U.S. branded competitor is Nityr, developed and marketed by Cycle Pharmaceuticals. Nityr contains nitisinone and is approved for HT-1. Its competitive value comes from an alternative branded supply source and commercial positioning in a rare metabolic disease market. [3]

Competitor	Product type	Competitive relevance
Nityr	Branded nitisinone	Direct U.S. competitor
Generic nitisinone manufacturers	Generic or multisource products	Potential price pressure
Orfadin capsules	Originator branded product	Established treatment and supply
Orfadin oral suspension	Originator pediatric formulation	Differentiation in young patients
Dietary management products	Adjunctive care	Supports, but does not replace, nitisinone

The competitive landscape differs by country. Some markets recognize multiple nitisinone products, while others rely on a single reimbursed product or centralized procurement. Regulatory approval does not guarantee commercial access because metabolic-disease reimbursement often depends on national formularies and specialist centers.

What formulations are protected by Orfadin?

Orfadin’s oral suspension is commercially important because it addresses a dosing problem that capsules do not solve well in infants and young children.

Oral suspension

The suspension may support:

• accurate weight-based dosing;
• administration to infants;
• reduced swallowing burden;
• continued use after newborn-screening diagnosis;
• improved caregiver practicality.

The suspension also creates a potential barrier to substitution. A competing company must demonstrate appropriate concentration, stability, dosing accuracy, palatability, packaging, and administration performance.

Capsules

Capsules remain relevant for older children and adults. They are easier to distribute and may have lower manufacturing and packaging costs. Their mature dosage-form profile makes them more vulnerable to generic or alternative-brand competition.

The formulation mix can therefore shift with patient age. Pediatric diagnosis supports suspension demand, while the prevalent adult population may continue to use capsules.

How strong is the Orfadin patent estate?

Orfadin’s patent estate is moderate at best when assessed against the broader nitisinone market.

Strengths

• Long clinical history and physician familiarity.
• Chronic treatment creates high switching friction.
• Pediatric suspension provides formulation differentiation.
• Rare-disease distribution is harder for new entrants to build.
• Manufacturing quality and supply reliability matter to metabolic centers.

Weaknesses

• The active ingredient is mature.
• Original orphan exclusivity has expired.
• Alternative branded nitisinone products are available.
• Capsule substitution is technically less difficult than biologic substitution.
• Patent protection is more likely to be narrow and product-specific.
• Payers can use therapeutic equivalence and procurement tools to reduce cost.

The estate is stronger commercially than it is legally. Patient continuity, specialist prescribing, and supply reliability may preserve share even where molecule-level patent barriers are weak.

What generic entry risks exist for Orfadin?

Generic entry risk is highest for capsules and lower for the oral suspension.

Capsule launch scenario

A capsule competitor could seek approval through an ANDA or another abbreviated pathway, depending on the product and regulatory jurisdiction. The likely effects would be:

• payer-driven substitution;
• discounts to specialty pharmacies and hospitals;
• lower net price;
• slower new-patient growth for Orfadin;
• retention of some patients because physicians prioritize continuity.

Oral suspension launch scenario

A suspension competitor would face more technical and regulatory work. It would need to address formulation equivalence, stability, dosing devices, packaging, and pediatric administration. That raises development costs and may delay entry.

Commercial launch timing

A realistic generic launch sequence would involve:

1. regulatory filing and patent certification;
2. patent litigation or a non-infringement strategy, if relevant;
3. FDA review;
4. launch after approval or patent resolution;
5. payer substitution and price competition.

The absence of a publicly prominent litigation event does not remove entry risk. It shifts the assessment toward product economics, approval timing, and reimbursement behavior.

What patent litigation and settlements affect Orfadin?

Orfadin’s competitive risk is not defined by a widely reported settlement involving a major generic challenger. The relevant legal questions are narrower:

• whether any live Orange Book patents remain listed;
• whether a competitor uses a formulation covered by those patents;
• whether a Paragraph IV notice has been filed;
• whether a 30-month stay applies;
• whether a settlement restricts launch timing;
• whether a competitor launches at risk.

The FDA Orange Book, Drugs@FDA records, PACER court filings, and company disclosures are the appropriate sources for confirming any current Paragraph IV litigation or settlement. [1,2,4]

How does Orfadin compare with other rare-disease drugs?

Orfadin differs from newer rare-disease therapies in several ways.

Metric	Orfadin	Newer biologic or gene therapy
Active ingredient	Small molecule	Often biologic or genetic medicine
Administration	Oral	Frequently injectable or infused
Treatment duration	Chronic	Chronic or potentially one-time
Manufacturing barrier	Moderate	Often high
Molecule patent life	Mature	Usually longer remaining life
Patient population	Ultra-rare	Rare to ultra-rare
Generic risk	Meaningful	Lower for biologics; biosimilar risk varies
Price strategy	Specialty chronic therapy	Often high upfront or high annual cost
Revenue profile	Recurring and stable	Potentially faster growth but higher volatility

Orfadin’s value is linked to continuity and prevalence rather than a large launch curve. Its downside is that mature small-molecule products usually face more direct price competition than biologics.

What licensing deals involve Orfadin?

Sobi is the principal commercial owner associated with Orfadin. The product originated in the Swedish Orphan rare-disease business and became part of Sobi’s portfolio through the company’s development and commercialization activities.

No major recent licensing transaction is required to explain Orfadin’s current market position. The product is commercially established, and the strategic issue is portfolio allocation rather than external licensing expansion. Any regional distribution, co-promotion, or rights arrangement should be assessed through local regulatory records and Sobi’s annual reports. [5]

What revenue exposure does Orfadin create for Sobi?

Orfadin is unlikely to be a primary determinant of Sobi’s consolidated valuation because Sobi has a broader portfolio with larger products and growth drivers. It still contributes strategic stability through:

• recurring chronic-treatment revenue;
• low dependence on new clinical readouts;
• specialist prescribing;
• a global rare-disease commercial infrastructure;
• relatively predictable patient retention.

The principal financial risks are product concentration in a small patient population, reimbursement pressure, supply interruption, and loss of share to Nityr or lower-priced nitisinone products.

The principal upside is gradual expansion from newborn screening, improved diagnosis, and continued use of oral suspension in pediatric patients.

Key Takeaways

• Orfadin is a mature nitisinone product for hereditary tyrosinemia type 1.
• Its commercial value comes from chronic treatment and specialist continuity, not high patient volume.
• Sobi does not provide a complete standalone Orfadin revenue series in current headline reporting.
• Core molecule protection is no longer the central barrier to competition.
• Formulation, pediatric usability, supply reliability, and specialist relationships provide the strongest practical defenses.
• Nityr is the leading direct branded competitor in the United States.
• Capsule products face greater generic risk than the oral suspension.
• Newborn screening is the clearest long-term volume driver.
• Orfadin is more likely to remain a stable cash-generating asset than a major growth product for Sobi.
• Current commercial risk is primarily price erosion and market-share substitution, not loss of the entire franchise.

FAQs

Is Orfadin a biologic or a small-molecule drug?

Orfadin is an oral small-molecule drug containing nitisinone. It is not a biologic, so biosimilar regulation does not apply.

Can Orfadin be substituted with Nityr?

Nityr contains the same active ingredient and is approved for HT-1, but substitution depends on national regulations, product labeling, payer policy, dosage form, and physician judgment.

Does Orfadin treat alkaptonuria in the United States?

The principal U.S. Orfadin approval is for hereditary tyrosinemia type 1. Regulatory treatment of alkaptonuria varies by jurisdiction and product authorization.

Why is Orfadin’s oral suspension commercially important?

It permits weight-based administration to infants and young children who cannot reliably swallow capsules. That creates practical differentiation and may reduce immediate substitution risk.

Is Orfadin exposed to biosimilar competition?

No. Nitisinone is a small molecule. The relevant competitors are branded alternatives, generics, and other nitisinone formulations rather than biosimilars.

References

1. U.S. Food and Drug Administration. (2023). Orfadin (nitisinone) prescribing information. FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. U.S. Food and Drug Administration. (2019). Nityr (nitisinone) prescribing information. FDA.
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.
5. Swedish Orphan Biovitrum AB. (2024). Annual report 2023. Sobi.